Search research articles
Contact Us
Filters
Showing results (111-120 of 272) with videos related to
Page
of 28
Sort By:
Therapeutic Advances in Musculoskeletal Disease
|
August 30, 2023
The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
Atul Deodhar, Dafna Gladman, Rebecca Bolce, et al.
Rheumatology (Oxford, England)
|
October 2, 2012
Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE)
Désirée van der Heijde, Jürgen Braun, Atul Deodhar, et al.
Rheumatology and Therapy
|
July 19, 2025
A Real-World Comparison of Clinical Effectiveness of Upadacitinib, Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors in Patients with Axial Spondyloarthritis After Switching from an Initial Tumor Necrosis Factor Inhibitor Treatment
Xenofon Baraliakos, Christopher D Saffore, Xiaolan Ye, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
September 19, 2024
Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo-Controlled, Phase 3 Study
Atul Deodhar, Jerzy Supronik, Alan Kivitz, et al.
ACR Open Rheumatology
|
September 30, 2023
Tofacitinib Efficacy and Safety in Patients With Ankylosing Spondylitis by Prior Biologic Disease-Modifying Antirheumatic Drug Use: A Post Hoc Analysis
Atul Deodhar, Helena Marzo-Ortega, Joseph Wu, et al.
RMD Open
|
May 9, 2024
Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status
Martin Rudwaleit, Atul Deodhar, Lars Bauer, et al.
The Journal of Rheumatology
|
April 1, 2026
Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study
Atul Deodhar, John D Reveille, Diane D Harrison, et al.
RMD Open
|
July 19, 2022
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
Jürgen Braun, Uta Kiltz, Atul Deodhar, et al.
Annals of the Rheumatic Diseases
|
November 13, 2014
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
Atul Deodhar, Jürgen Braun, Robert D Inman, et al.
Rheumatology (Oxford, England)
|
June 4, 2018
Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
Désirée van der Heijde, Jürgen Braun, Atul Deodhar, et al.
Page
of 28
Search research articles
Search
Showing results (111-120 of 272) with videos related to
Sort By:
Page
of 28
Therapeutic Advances in Musculoskeletal Disease
|
August 30, 2023
The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2
Atul Deodhar, Dafna Gladman, Rebecca Bolce, et al.
Rheumatology (Oxford, England)
|
October 2, 2012
Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE)
Désirée van der Heijde, Jürgen Braun, Atul Deodhar, et al.
Rheumatology and Therapy
|
July 19, 2025
A Real-World Comparison of Clinical Effectiveness of Upadacitinib, Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors in Patients with Axial Spondyloarthritis After Switching from an Initial Tumor Necrosis Factor Inhibitor Treatment
Xenofon Baraliakos, Christopher D Saffore, Xiaolan Ye, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
September 19, 2024
Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo-Controlled, Phase 3 Study
Atul Deodhar, Jerzy Supronik, Alan Kivitz, et al.
ACR Open Rheumatology
|
September 30, 2023
Tofacitinib Efficacy and Safety in Patients With Ankylosing Spondylitis by Prior Biologic Disease-Modifying Antirheumatic Drug Use: A Post Hoc Analysis
Atul Deodhar, Helena Marzo-Ortega, Joseph Wu, et al.
RMD Open
|
May 9, 2024
Long-term clinical outcomes of certolizumab pegol treatment in non-radiographic axial spondyloarthritis stratified by baseline MRI and CRP status
Martin Rudwaleit, Atul Deodhar, Lars Bauer, et al.
The Journal of Rheumatology
|
April 1, 2026
Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study
Atul Deodhar, John D Reveille, Diane D Harrison, et al.
RMD Open
|
July 19, 2022
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
Jürgen Braun, Uta Kiltz, Atul Deodhar, et al.
Annals of the Rheumatic Diseases
|
November 13, 2014
Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
Atul Deodhar, Jürgen Braun, Robert D Inman, et al.
Rheumatology (Oxford, England)
|
June 4, 2018
Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
Désirée van der Heijde, Jürgen Braun, Atul Deodhar, et al.
Page
of 28